Purpose

The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  1. Moderate disease with at least a 30% increase in CRP within 36 hours of admission, and with increasing oxygen requirements. 2. All patients with severe disease with evidence of escalating oxygen requirements 3. The presence of secondary bacterial infections as a probable cause of increasing CRP levels was excluded in all selected patients. 4. Pulmonary embolism and /or cardiac dysfunction were excluded as probable causes of worsening hypoxia in all selected patients.

Exclusion Criteria

  1. All patients on other treatment modalities- Remdesivir and/or Convalescent plasma who showed evidence of clinical improvement as per decrease in CRP levels and/or oxygen requirements were excluded. 2. Patient with associated COPD exacerbation who would benefit from the use of steroids. 3. Patients with Diabetic ketoacidosis, hyperglycemic hyperosmolar state, active concurrent bacterial infections. 4. Patients with history of steroid-induced mania and/or psychosis.

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
SARS-CoV2 patients that received dexamethasone
  • Drug: Dexamethasone
    4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.

Recruiting Locations

More Details

NCT ID
NCT04445506
Status
Completed
Sponsor
The Miriam Hospital

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.